In. Liposomal accumulation in tumors and organs was followed over time by SPECT/CT imaging. We observed that fast growing xenografts, which may be less representative of tumor development in patients, showed higher liposomal accumulation as compared to slow growing xenografts. Additionally, several other parameters determining the EPR effect were evaluated, such as blood and lymphatic vessel density, intratumoral hypoxia, and the presence of macrophages. The investigation of various parameters showed a few correlations. Although hypoxia, proliferation and macrophage presence were associated with tumor growth, no hard conclusions or predictions could be made regarding the EPR effect or liposomal uptake. However liposomal uptake was significantly correlated with tumor growth, with fast growing tumors showing a higher uptake, although no biological determinants could be elucidated to explain this correlation.
INTRODUCTION
Almost all nanocarriers, including liposomes (1) , and many other anti-cancer drugs rely on the enhanced permeability and retention (EPR) effect for accumulation in tumor tissue. The EPR effect is defined as the process of extravasation of large molecules from leaky tumor vasculature, leading to accumulation in tumor tissue (2) . The EPR effect is dependent on many biological parameters, with the development of the abnormal tumor vasculature playing a major role, although other parameters such as the composition of the surrounding stroma, absence of functional lymphatics and presence of tumor infiltrating macrophages, also play an important role (3) . Abnormally upregulated growth factors affect the vasculature of the tumor (4) and lead to large endothelial junctions at the luminal surface resulting in a leaky vasculature (5) . In addition, vessels lack smooth muscle cell layers and supporting cells (6) , and the fast recruitment of blood vessels results in tumor neovasculature that is not hierarchically organized causing a heterogeneous spatial distribution (4, 7, 8) . Finally, tumors overexpress many permeability enhancing factors, which contribute to an enhanced EPR effect (9) . These facts suggest that most tumors may be susceptible to nanoparticle treatment, but thus far such particles only show a limited effect in vivo due to various barriers such as the mononuclear phagocyte system, extracellular matrix, low pH, low oxygenation and high interstitial fluid pressure (10) (11) (12) . The intra-and inter-tumoral heterogeneity are major factors influencing the EPR effect, especially in patients, which have a much slower tumor and vessel development (13) .
The FDA approved liposomal doxorubicin (Doxil or Caelyx) is one of the most succesful nanoparticle drugs for several cancer types (14) (15) (16) (17) . Unfortunately Doxil has a limited effect on overall survival when compared to conventional chemotherapy (3) , as has been shown in various clinical trials (17) (18) (19) . This and previous results suggest that tumor physiology influences the efficacy of nanoparticle drugs, possibly due to variations in the EPR effect (20) .
Since the EPR effect is essential for the efficacy and mode of action of liposomes in vivo, the aim of this study was to investigate major parameters influencing EPR and their effects on liposomal uptake in tumor xenografts. To this end, we injected unloaded, long-circulating, pegylated Doxillike liposomes to determine liposomal tumor accumulation. Various human xenograft tumor models, including squamous cell carcinoma, breast cancer, and pancreatic cancer were selected based on tumor growth rate, taking into consideration that slow-growing tumors are more representative of tumor growth in patients. Our results show that it is difficult to elucidate single determinants of the EPR effect and we therefore suggest that liposomal uptake and distribution in tumors is a multifactorial process involving physiological and morphological parameters.
MATERIAL AND METHODS

Preparation of Unloaded Doxil Liposomes
Doxil liposomes were prepared as described in the Supplemental Material and Methods.
Cell Lines
All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and routinely cultured as described in Supplemental Material and Methods. In was incubated per µmol liposomes for 15 min at room temperature, 2.5 M Sodium acetate was used to set the pH at 5.0.
ITLC-SG (silica gel coated paper (Varian Inc.); 0.1 M Sodium citrate, mobile phase) was performed to ascertain complete labeling (21) . Due to the molar excess of DTPA-lipid over 111 In, lipid labeling efficiencies of > 99% was achieved. Prior to injections, the volume was adjusted to 200 µL per µmol of liposomes with HEPES buffered saline (10 mM HEPES, 135 mM NaCl, pH 7.4).
In Vivo Biodistribution Studies
Tumor inoculation of NMRI nu/nu mice is described in the Supplemental Material and Methods. 
Ex vivo biodistribution
Tumors and tissue samples (blood (cardiac puncture), heart, lung, liver, spleen, pancreas, kidney, stomach, duodenum, caecum, colon, tail, and muscle) were harvested and weighed. Radioactivity In (t1/2 = 2.81 days). The injected dose was calculated by measuring the syringe before and after injection.
Immunohistochemical Staining
After the final scan, pimonidazole (60 mg/kg body weight) was injected i.p. and allowed to circulate for 4 h before dissection of tumor and organs. Harvested tumors were snap-frozen in liquid nitrogen and frozen tumor sections were used for immunohistochemical staining as described in Supplemental Material and Methods. Sections were stained for blood vessels (CD31), pegylated liposomes (PEG), macrophages (CD11b), lymphatic vessels (LYVE-1), vessel integrity (Collagen IV) and hypoxia (pimonidazole).
Tile scans of fluorescently stained tumor sections were acquired using a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss B.V., Sliedrecht, the Netherlands) with a Plan-Neofluar 10x objective. Quantifications were performed with ImageJ software, using manual thresholding (range 0-255) for density analysis and co-localization threshold tool to ascertain the ratio between PEG and CD31, and collagen IV and CD31. To avoid regional bias, all quantifications were performed on whole tile scans of tumor sections.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA). Differences between fast, intermediate, and slow growing xenografts were evaluated using one-way ANOVA with non-parametric Kruskal-Wallis H test and Dunn's multiple comparison post-test. Comparisons between the high and low uptake groups were performed using the two-tailed Mann-Whitney U test. Correlation analysis between the various parameters evaluated in this study was performed using the Spearman's rho test. All statistical tests were two-sided, and p value lower than 0.05 was considered statistically significant.
RESULTS
Characterization of Liposomes
Liposomal characteristics, such as size and polydispersity were confirmed to be similar to Doxil and are described in detail in the Supplemental Results.
To perform image-guided delivery, the liposomes were labeled with 111 In for SPECT imaging. In for SPECT imaging.
Volume-of-interest (VOI) was drawn to quantify liposomal accumulation in tumor and heart. In -DTPA is rapidly cleared from circulation (26) .
Ex Vivo Organ Biodistribution
Radioactivity uptake was measured after resection of the organs and other relevant tissues and is shown per tumor type in Figure 2 , and in more detail for all analyzed organs, including the tumor, in Supplemental Figure 3 . The tumors are again arranged from fast to slow growing, with levels of uptake ranging from PANC-1 (1.51 ± 0.11 %ID/g) on the low end, to CFPAC-1 (7.99 ± 3.59 %ID/g) on the high end. A trend was observed between tumor growth and liposomal uptake (Table 1 , p = 0.0104), although outliers, such as A431, BxPC-3, and MDA-MB-468, indicate that other factors are important and may be influencing liposomal accumulation. The reason for this was investigated in more detail using immunohistochemical stainings (see below), but it is for example known that the presence of necrotic or poorly vascularized tumor cores in fast growing tumors may inhibit liposomal uptake (27) . The majority of the liposomes accumulate in the liver, spleen, and tumor; after which they are cleared. Liposomal uptake in vivo was compared with other modalities used to detect liposomal uptake and the morphological parameters thought to influence the EPR effect and nanoparticle uptake. To this end, the tumors were subdivided in high and low uptake groups, the high uptake group included CFPAC-1, HPAF-II, and MDA-MB-231 xenografts. Table 1 
Immunohistochemistry
To further investigate the underlying mechanisms of the EPR effect and to find possible explanations for the observed variations in liposomal tumor uptake, several morphological parameters were investigated using immunohistochemistry. In Figure 3A , the percentage of total tumor areas positive for liposomal content was calculated using an anti-PEG antibody. This shows a significant correlation with the in vivo and ex vivo quantifications (Supplemental Table   2 ; p = 0.007 and p < 0.001, respectively). Additionally, the intratumoral localization of the liposomes was determined in relation to blood vessels (CD31) showing that the majority of liposomes had indeed extravasated from the vessels (Figure 3C ), although the distance travelled from the vessels is minimal. The percentage of extravasated liposomes was calculated by subtracting the number of CD31-colocalized liposomes from the total number of liposomes present in the area. This is depicted in Figure 3D , where an example is given of a CD31 staining (green), total PEG staining (red) and the calculated colocalized liposomes (PEG in; yellow), which shows liposomes within and extravasated from these vessels (shown in PEG composite in yellow and red respectively). Figure 3B shows HPAF-II and PANC-1 frames to demonstrate the difference of liposome localization in tumors with high and low uptake, respectively. Although nanoparticle distribution and accumulation is undeniably related to the presence of blood vessels (28), Figure 4A shows that the number of vessels (depicted in percentage Mean Vessel Density) cannot be used to predict the degree of liposomal uptake. For example, AsPC-1 and UACC-893 have a similar uptake of liposomes, depicted with in vivo, ex vivo, and immunohistochemical quantifications, but the mean vessel density of UACC-893 is three times higher than that of AsPC-1 (Supplemental Figure 4A) . As mentioned before, the factors influencing the EPR effect and the uptake of liposomes are more complex. The mononuclear phagocytic system (MPS) also has a major influence on the delivery of liposomes, although detection by the MPS may be reduced by pegylation (29, 30) . Monocytes internalize liposomes, after which the drug may be released, resulting in toxic effects to the monocytes. Figure 4B shows that the percentage of macrophages in the tumor tissue is in general relatively low, with the exception of MDA-MB-468 (5.70 ± 2.26 %). This might explain why a slow growing tumor (5 months) with a poor mean vessel density (1.79 ± 0.42 %) still has a considerable liposomal uptake (2.87 ± 1.05 %). Hypoxia is usually correlated with poor vascularization and indicative of poor drug uptake. Due to unrestrained tumor growth, cells move beyond the distance over which oxygen can diffuse (circa 150 µm) and drugs targeting fast dividing cells will usually be less effective (31, 32) . All tumors show a comparable degree of hypoxia ( Figure 4C ), suggesting that this aspect plays a minor role in these tumor models. The functionality of both blood and lymphatic vessels is thought to be of great importance to the EPR effect and eventual uptake of macromolecules (2) . We therefore incorporated a lymphatic marker (LYVE-1) and a collagen IV antibody to measure lymphatic vessel density and collagen IV support of blood vessels. The lymphatic vessels ( Figure 5A and Figure 5C and 5D). In order to decipher possible associations between liposomal uptake and the various morphological parameters tested, we performed a correlation analysis (Supplemental Table 2 ). Although there was a significant correlation between the percentage PEG and the liposomal uptake in vivo, no further significant correlations related to other tested morphological parameters could be found. A multivariate analysis requiring a much larger data set may in future show whether multiple parameters are responsible.
DISCUSSION
The EPR effect, first described by Matsumura and Maeda in 1986 (2), shows tumor-specific accumulation of large molecules, dependent on the following parameters: the size of the molecule(s) should be larger than the renal clearance threshold (7 nm) to prevent fast clearance; the molecule should have characteristics that ensure a long circulation time to increase the chance for extravasation; and the nature of the tumor has to be such that it will ensure retention of these molecules, usually ranging from days to weeks, leading to enhanced efficacy. These properties distinguish the EPR effect needed for therapeutic purposes from targeting of low-molecular weight molecules with a short half-life and fast clearance, which are more suited for imaging purposes (33) . By utilizing the EPR effect, pegylated liposomes such as Doxil, have been successful in the treatment of certain cancers.
This study has consolidated that pegylated liposomes can accumulate in various solid tumors, although considerable differences in uptake were observed. Uptake levels ranged from PANC-1 to CFPAC-1 at the low to high end, respectively. There is a trend between liposome accumulation and the speed of tumor growth. Tumors, such as squamous cell carcinoma A431, showed very fast tumor growth, but had limited liposomal accumulation in the tumor. This could be explained by the high growth rate and relatively large size of these tumors. Angiogenesis is increased during tumor growth (34) and the tumor will grow exponentially until sufficient vascularization can no longer be sustained. This leads to hypoxic or necrotic tumor cores, which are more difficult to reach with anti-cancer drugs. Before this point is reached, the chaotic development of tumor vasculature together with the obstruction and collapse of lymphatic vessels at the tumor core will lead to an enhanced EPR effect and possibly an increased accumulation of nanoparticles (2) . Lymphatic vessel density evaluation revealed that most tumors had an impaired lymphatic system aiding liposome accumulation. The exception was the intermediate growing BxPC-3 which had a high lymphatic vessel density and a well-developed mean vessel density, although it still showed a relatively poor liposomal accumulation. Although it has been hypothesized that normalizing the vasculature, extracellular matrix and lymphatic vessels would lead to better delivery of drugs (35) , this may therefore not always hold true for liposomal drugs.
Normalization of vessels will lead to a less leaky vasculature, which might impair the EPR effect.
It has also been shown that mean vessel density correlates with the degree of liposome accumulation (28) A. Percentage of liposome uptake calculated from immunohistochemical staining of PEG, which shows a comparable uptake as in vivo/ex vivo quantifications. B. Representative images of tumor periphery and center indicate that uptake in the periphery is higher in both high and low uptake tumors. C/D. Extravasated liposomes calculated for all tumors based on the total PEG (red) minus PEG colocalized (yellow) with blood vessels (CD31, green), leading to a final composite figure showing the colocalized (yellow) and extravasated (red) liposomes. The degree of extravasation is relatively high in all tumors. All quantifications were performed on whole tile scans of the tumorsections. Scale bars, 100 µm. A. LYVE-1 staining indicates the presence of lymphatic vessels in the different tumors, which can be used to interpret possible drainage of the tumor. B. Lymphatic vessel (LYVE-1) to blood vessel (CD31) ratio, indicative of the supply and drainage of tumor tissue. C. Collagen IV is important for the support of blood vessels and is used as a marker for healthy blood vessels. The degree of collagen is comparable between tumors. D. Colocalization of collagen IV and blood vessels (CD31) supports the observation that most tumor vessels are mature and supported by collagen, with the exception of MDA-MB-468. All quantifications were performed on whole tile scans of the tumor sections. 
